Last updated: 2026-09-05 02:03:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Incyte Genomics Inc. (INCY) operates in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector and is listed on NASDAQ. The stock is currently priced at $126.75, with a market capitalization of $26.11B and a P/E ratio of 16.09. Over the past 52 weeks, its price has ranged from $81.09 to $132.60. This page covers its latest market performance, valuation, price trends and company information.
$26.11B | |
$126.46 | |
$153.15 | |
$1.85 | |
$128.00 | |
639.98K | |
-- | |
16.09 | |
$132.60 | |
$81.09 | |
-- | |
-- |
Incyte Genomics Inc. (INCY) last closed at $128.00 as of 2026-09-04 23:50:00, unchanged from the previous close of $128.00.
During the latest regular trading session, INCY traded between $1.85 and $153.15, with a volume of 639.98K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Incyte Genomics Inc. (INCY) moved from $122.66 to $126.75, representing a gain of 3.34% ($4.09).
The stock traded between $126.14 and $128.02 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 1.27 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 88.6%
INCY is currently trading at $126.75, placing it 88.6% of the way from its 52-week low of $81.09 to its 52-week high of $132.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
| Industry | SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH |
| Employees | 2844 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Incyte Genomics Inc. (INCY) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.